Tokyo-based Chugai Pharmaceutical Co., Ltd. has officially opened a new
laboratory in Singapore that will conduct research into new antibody drugs.
Tokyo-based Chugai Pharmaceutical
Co., Ltd. officially opened on Friday a new laboratory in Singapore that will
conduct research into new antibody drugs.
The new Singapore-based Chugai
Pharmabody Research Pte. Ltd. (CPR) will screen antibody drug candidates for
therapeutic potential using Chugai’s proprietary antibody engineering
technologies.
The $1.5 million facility will be
located at Singapore’s Biopolis R&D hub and employ approximately 60
researchers. A*STAR Chief Scientist David Lane is the chairman of the board of
the venture.
According to a Chugai press
statement, CPR aims to generate five or more drug candidates per year for its
drug pipeline. It will make use of its proprietary recycling antibody
technology, which uses a single antibody molecule to repeatedly block the
function of the target antigen and eliminate it from plasma.
CPR will be Chugai’s fourth
satellite research institute following its C&C Research Laboratories in
South Korea; Pharmalogicals Research Pte. Ltd. in Singapore; and Forerunner
Pharma Research Co., Ltd. in Tokyo.
Chugai Pharma’s latest venture follows a number of Japanese companies that are setting up R&D hubs in Singapore.
Chugai Pharma’s latest venture follows a number of Japanese companies that are setting up R&D hubs in Singapore.
In April 2012, Toshiba
Corporation opened an Aqua Research Center at the WaterHub in
Singapore, its first water treatment R&D center located outside of Japan.
In February 2012, petrochemical
manufacturer Sumitomo
Chemical opened a solution styrene-butadiene rubber (S-SBR)
manufacturing plant in Singapore.
——
Source: Chugai
Pharma
No comments:
Post a Comment